References
- Lataillade TD, Billy A. Market access in Europe: An exclusive survey on biopharmaceutical industry trends. Cegedim Relationship Management. 2010. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Whitepaper_June_2010.pdf [cited 14 May 2014].
- Hulten EV, Lataillade TD. Market Access in Europe 2011. Cegedim Relationship Management. 2011. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Rpt_June_2011.pdf [cited 30 April 2014]..
- Wang L, Richardson R. Planning for change: Adapting to shifts in the global market access landscape. Campbell Alliance; No date. Available from: http://www.campbellalliance.com/articles/Campbell_Alliance_Global_Market_Access_Article.pdf [cited 14 June 2014]..
- Mikkelsen JS. Market access for medical technology & pharmaceutical companies: An organizational priority in times of economic austerity and reform. 2012. Available from: http://um.dk/en/~/media/USA/Market Access for Medical Technology Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform.pdf [cited 24 April 2014]..
- Forcellina A, Akannac C. Managing talent to meet pharma's next great challenge: Global market access, 2013. 2013; Egon Zehnder International. Available from: http://www.egonzehnder.com/files/managing_talent_to_meet_pharmas_next_great_challenge.pdf [cited 17 October 2014]..
- Billy A. Market access challenges driving pharma change. Cegedim Dendrite. 2010. Available from: http://www.pharmaphorum.com/articles/market-access-challenges-driving-pharma-change [cited 24 May 2014].
- McClearn C, Croisier T. Big pharma's market access mission. Deloitte University Press. 2013. Available from: http://dupress.com/articles/big-pharmas-market-access-mission/ [cited 4 June 2014]..
- Arx RV, Bernard C. Leveraging success factors for market access in the life sciences industry. 2009; Capgemini Consulting and Cegedim dendrite. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/Market_Access_Whitepaper.pdf [cited 24 May 2014].
- Olivier K, Van De Kam HB. Stakeholder management. Capgemini Life Sciences. 2010. Available from: http://www.capgemini.com/resource-file-access/resource/pdf/Stakeholder_management_0.pdf [cited 17 May 2014].
- Market access challenges, Pharma Phorum, Interview Ulf Staginnus, Franchise Head Oncology, Health Economics & Reimbursement at Amgen. 2012. Available from: http://www.pharmaphorum.com/articles/market-access-challenges [cited 20 October 2014].
- Taking advantage of global opportunities following the Nycomed acquisition – Takeda's strategy focused on emerging markets. 2012. Available from: https://www.takeda.com/investor-information/results/pdf/2012/qr2012_q2_e_en.pdf [cited 17 October 2014]..
- Mehta P. How can insight-driven commercial models deliver value in cardiovascular therapeutic markets? The IHS Global Insight Health care and Pharmaceuticals Practice. 2011. Available from: http://www.ihs.com/pdfs/IHS-ebook-cardiovascular-therapeutic-markets-insight-driven-commercial-models.pdf [cited 27 May 2014]..